Jump to top menu Jump to main menu Jump to content
Profile picture of Ron Mathijssen
Principal Investigator

Prof. A.H.J. (Ron) Mathijssen, MD, PhD

  • Department
  • Medical Oncology
  • Focus area
  • Tailored therapy of systemic anti-cancer agents, anti-hormonal therapy, tyrosine kinase inhibitors and immunotherapy
Contact  

About

Introduction

Ron Mathijssen is Head of the Section Translational Pharmacology and is Professor Individualized Oncological Pharmacotherapy.

He studied medicine at the Erasmus University Rotterdam for which he received his MD degree in 2000. Two years later he defended his thesis (cum laude) entitled: ‘Irinotecan: from Clinical Pharmacokinetics to Pharmacogenetics’. Subsequently, he became Internist, Medical Oncologist, and Clinical Pharmacologist.

Since 2013, he is a professor in Individualized Oncological Pharmacotherapy at the Department of Medical Oncology, heading the section of Translational Pharmacology (CP); including the laboratory TP and the workgroup Personalized Medicine.

 

Field(s) of expertise

His main research is focused on ‘tailored therapy’ of systemic anti-cancer agents like chemotherapy, anti-hormonal therapy, tyrosine kinase inhibitors, and immunotherapy.
To implement therapeutic drug monitoring (TDM) in daily oncological clinical practice is one of his major goals for the coming years.
 
He published over 250 peer reviewed papers and book chapters. In addition, he is the chair of the Dutch Pharmacology Oncology Group (www.dpog.nl); a nationwide collaboration to individualize the dosing of (oral) anti-cancer drugs.

Education and career

Ron Mathijssen studied medicine at the Erasmus University Rotterdam for which he received his MD degree in 2000. Two years later he defended his thesis (cum laude) entitled: ‘Irinotecan: from Clinical Pharmacokinetics to Pharmacogenetics’. Subsequently, he became Internist, Medical Oncologist, and Clinical Pharmacologist.

Since 2009 he is Staff Member of the dept. of Medical Oncology.

Publications

Teaching activities

Since 2013, he is a professor in Individualized Oncological Pharmacotherapy at the Erasmus MC Cancer Institute. He supervised theses of many PhD students (usually MDs and PharmDs).
He is also Specialty Trainer for Clinical Pharmacologists at Erasmus MC.

Other positions

- Chair Research Advise Committee Erasmus MC (MRACE) Grant committee
- Organizing Committee ICPAD
- Chair Dutch Pharmacology Oncology Group (DPOG)
- Boardmember Emil Starkenstein Stichting and Vera Bonta Prize
- Clinical Advisory Board (CAB) Oncode
- Member Certificeringscie NIV
- Member Certificeringscie NVKF&B
- Organizing Committee COIG Clinical Pharmacology (NIV)
- Member Scientific Counsel Dutch Cancer Society (KWF)

Scholarships, grants, and awards

To fund this research he obtained funding by KWF, Alpe d'Huzes, Zon-Mw, etc. 
 
For his thesis he obtained the 'Thesis of the Year' award by the Dutch Society for Medical Oncology.

My Groups